Plural C=o Groups Patents (Class 514/705)
  • Patent number: 8999399
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Grant
    Filed: November 14, 2009
    Date of Patent: April 7, 2015
    Assignee: Bose Chemie GmbH
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Publication number: 20140369953
    Abstract: Disclosed are compositions comprising a) an antimicrobial agent, which is selected from the group consisting of biocides containing halogen atoms and/or containing phenolic moieties, formic acid, chlorine dioxide, chlorine dioxide generating compounds, dialdehydes; components containing an antimicrobial metal such as antimicrobial silver, and b) a polyamine, especially a polyethylenimine. The polyamine is effective as a booster for the antimicrobial agent.
    Type: Application
    Filed: February 19, 2013
    Publication date: December 18, 2014
    Applicant: BASF SE
    Inventors: Janina Purschwitz, Stephan Hüffer, Alejandra Garcia Marcos, Menno Hazenkamp
  • Publication number: 20140271537
    Abstract: The present invention generally relates to deuterium-enriched aldehydes, compositions comprising deuterium-enriched aldehydes, and methods for slowing the rate of aldehyde autoxidation. In one aspect, the present invention provides a composition comprising a compound of structure 1: wherein: there are at least 6×1018 molecules of the aldehyde and Rx is hydrogen, wherein the deuterium isotope in Rx is in an amount greater than 0.10 percent of the hydrogen atoms present in Rx.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Inventor: Anthony W. Czarnik
  • Patent number: 8729135
    Abstract: This invention relates to a stabilized aqueous glutaraldehyde solution including 0.005% to 45% m/v, suitably 10% to 45% m/v solution of glutaraldehyde, an alcohol ethoxylate non-ionic surfactant, a buffer and a sufficient amount of a pH modifier to bring the pH of the solution to 6.0 to 8.5. The glutaraldehyde and the alcohol ethoxylate non-ionic surfactant are chemically bound together, suitably by complexing. These stable solutions can be stored for a period of at least six months without the glutaraldehyde polymerizing or the pH dropping below 5.0.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: May 20, 2014
    Inventor: Antonietta Pamela Martin
  • Publication number: 20140121646
    Abstract: Methods and devices for preventing nutrient absorption in the small intestine wherein a medical device is passed through the esophagus, and positioned in the small intestine to treat the interior mucosal surface of the small intestine, causing a reduced capacity for nutrient absorption in the treated segment. In one embodiment, the device contains an element that isolates the segment to be treated and allows for the delivery and removal of treatment agents and neutralizing agents.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 1, 2014
    Inventors: David Lodin, Kemal Schankereli, Howard Lederer
  • Patent number: 8658190
    Abstract: The addition of alcohol plus acetate salts unexpectedly enhanced the tuberculocidal activity of glutaraldehyde, and decreased the fumes of glutaraldehyde from the formula of a high-level disinfectant.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: February 25, 2014
    Assignee: DFB Technology, Ltd.
    Inventor: Norman A. Miner
  • Patent number: 8580789
    Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: November 12, 2013
    Assignees: The Cleveland Clinic Foundation
    Inventors: Ronald R. Krueger, William J. Dupps, Stephen Trokel, Ivey Thornton
  • Patent number: 8506940
    Abstract: Compositions for effectively delivering a water-soluble active material to a surface comprise: (a) from about 1% to about 30%, by weight of the composition, of a dialkyl quaternary ammonium compound having the formula: wherein R1 and R2 are independently C12 to C20 saturated alkyl chains; Y is wherein R4 is ethyl or isopropyl; R3 and R5 are independently methyl, ethyl, hydroxyethyl, or hydroxypropyl; m is 1, 2, or 3; n is 1 or 2; p is 0 or 1; and X? is a suitable anion; (b) from about 0.01% to about 10%, by weight of the composition, of water-soluble active material having a ClogP of less than about 2.0; and (c) at least about 60%, by weight of the composition, of water; wherein the compositions contain vesicles having a vesicle permeability index of less than about 1.3.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: August 13, 2013
    Assignee: The Procter & Gamble Company
    Inventors: Hugo Jean-Marie Demeyere, Gunnel Ingegard Matilda Johnasson, Mangus Bo Nydén
  • Publication number: 20130172425
    Abstract: The present invention is generally directed to compositions and methods for the treatment of an infectious disease of the foot of an animal. One aspect of the invention is directed to a method for preventing and/or treating one or more infectious diseases of the hoof in animals, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent, wherein the cross-linking agent is not formaldehyde; and administering the composition to a lower leg and hoof area of said animal to prevent and/or treat said one or more infectious diseases. Another aspect of the invention is directed to a copper-free and zinc-free composition for the treatment and/or prevention of one or more infectious diseases of the hoof in animals, comprising at least one cross-linking agent, wherein said cross-linking agent is not formaldehyde.
    Type: Application
    Filed: December 18, 2012
    Publication date: July 4, 2013
    Applicant: AGROCHEM, INC.
    Inventor: AgroChem, Inc.
  • Publication number: 20130123369
    Abstract: The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 16, 2013
    Inventors: Nicola Di Maiuta, Patrick Schawarzentruber, Matthias Buri, Patrick Arthur Charles Gane
  • Publication number: 20130101674
    Abstract: The present invention relates to a biocidal coating composition comprising a biocide and an organofunctional silane oligomer which is distinct from the biocide. Such compositions are suitable for application to a substrate surface to provide long term disinfection on the surface of the substrate. The organofunctional silane oligomer prolongs the action of the biocide on the surface of the substrate, and provides improved surface-retention of the biocide.
    Type: Application
    Filed: May 20, 2011
    Publication date: April 25, 2013
    Applicant: GX LABS HOLDINGS LIMITED
    Inventor: John Toft
  • Publication number: 20130096202
    Abstract: The present invention relates to disinfecting and sterilising solutions containing glutaraldehyde. In particular, the invention provides solutions which are stabilised through the use of a unique combination of additives, including a bioflavonoid antioxidant (or other phenolic antioxidant) and an alkyl polyglucoside surfactant.
    Type: Application
    Filed: June 24, 2011
    Publication date: April 18, 2013
    Applicant: GX LABS HOLDINGS LIMITED
    Inventor: John Toft
  • Publication number: 20130040916
    Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Application
    Filed: October 12, 2012
    Publication date: February 14, 2013
    Applicant: ESPERION THERAPEUTICS, INC.
    Inventor: Esperion Therapeutics, Inc.
  • Publication number: 20120172337
    Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Application
    Filed: March 8, 2012
    Publication date: July 5, 2012
    Applicant: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20120107415
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Application
    Filed: November 14, 2009
    Publication date: May 3, 2012
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Publication number: 20120034313
    Abstract: A chemical blend that simultaneously kills bacteria and suppresses the production of hydrogen sulfide (H2S) includes both a first chemical, which may be a glutaraldehyde, a tetrakishydroxymethyl phosphonium sulfate (THPS), a quaternary amine compound, a thiocyanate, a carbamate, a cinnamaldehyde, an alkyl dimethyl benzyl ammonium chloride, and/or a diamine diacetate; a second chemical which is a quinone; optionally a third chemical, which is a phosphate compound and a solvent which includes monoethylene glycol. The chemical blend has shown synergistic results for killing bacteria and/or suppressing the production of hydrogen sulfide as compared with the addition of the results of each of the components of the blend used separately.
    Type: Application
    Filed: March 15, 2011
    Publication date: February 9, 2012
    Applicant: Baker Hughes Incorporated
    Inventors: Jodi Beth Wrangham, Sebastian D. Mancuso
  • Patent number: 8088829
    Abstract: A novel combination of OPA, a surfactant, and alcohol. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethylbenzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters the free energy of that surface. The alcohol is preferably isopropyl alcohol. The OPA is the dialdehyde C6H4(CHO)2, which produces an inherent bacteriostatic effect and lowers surface tension and thus aids in the spread of the dual quat on the biofilm covered surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the dual quat and the application surface. This multi purpose component helps create the unique aspect of the formulation.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: January 3, 2012
    Inventor: Howard Martin
  • Publication number: 20110280824
    Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.
    Type: Application
    Filed: July 26, 2011
    Publication date: November 17, 2011
    Applicant: Tyco Healthcare Group LP
    Inventor: Joshua B. Stopek
  • Publication number: 20110197781
    Abstract: The present invention relates to a process for stabilizing aqueous preparations of minerals by adding reuterin to the aqueous preparations, to the use of reuterin for the stabilization of such aqueous mineral preparations, and the aqueous mineral preparations containing reuterin.
    Type: Application
    Filed: August 19, 2009
    Publication date: August 18, 2011
    Inventors: Patrick Schwarzentruber, Nicola Di Maiuta
  • Publication number: 20110201692
    Abstract: The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are methods for rapidly reducing a microbe or a virus from surfaces including surfaces of indwelling medical devices and organic surfaces such as skin and sutures, and inorganic surfaces such as hospital equipment, pipelines etc.
    Type: Application
    Filed: April 27, 2011
    Publication date: August 18, 2011
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Issam Raad
  • Publication number: 20110152378
    Abstract: There is provided a disinfectant composition comprising (a) 15% to 40% biocide, by weight based on the weight of said composition, (b) 15% to 40% water, by weight based on the weight of said composition, and (c) 20% to 70% solvent, by weight based on the weight of said composition, wherein said solvent comprises one or more glycol ether.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 23, 2011
    Inventors: Antonio Arzu, Ute H. Bertheas, Paul Foley, Stephanie L. Hughes, Philip A. Keene, Pierre M. Lenoir
  • Publication number: 20110152365
    Abstract: In the present invention, there is provided a disinfectant composition comprising (a) 15% to 49.75% biocide, by weight based on the weight of said composition, (b) 15% to 49.75% water, by weight based on the weight of said composition, and (c) 0.5% to 60% soluble salt, by weight based on the weight of said composition.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 23, 2011
    Inventors: Antonio Arzu, Ute H. Bertheas, Paul Foley, Stephanie L. Hughes, Philip A. Keene, Pierre M. Lenoir
  • Publication number: 20110081423
    Abstract: Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition.
    Type: Application
    Filed: July 28, 2010
    Publication date: April 7, 2011
    Inventors: Norman R. Weldon, Matthew F. Ogle
  • Patent number: 7884089
    Abstract: An antimicrobial coating composition consisting essentially of 70 to 80 wt. percent water; 5 to 10 wt. percent methyl alcohol; 3 to 8 wt. percent octadecyl dimethyl trimethoxy silylpropyl-ammonium chloride; 1 to 5 wt. percent chloropropyl trimethoxysilane; 0.5 to 1.5 wt. percent aminopropyltrialkoxysilane; 0.5 to 1.5 wt. percent of a surfactant; 1 to 1.5 wt. percent of an anti-microbial agent; and 0.5 to 2.5 wt. percent sulfuric acid.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: February 8, 2011
    Assignee: Xurex, Inc.
    Inventor: Bo H. Gimvang
  • Publication number: 20100249245
    Abstract: Disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant having a cloud point in the range of about 30° C. to 50° C. Also disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant, wherein the second surfactant is a quaternary ammonium compound. A process for preparing the compositions of the invention is also disclosed. The compositions of the invention are low or substantially non-foaming under high pressure, high temperature conditions, thus allowing maximum benefit from the new, more reliable, generation of automated endoscope reprocessing machines.
    Type: Application
    Filed: March 28, 2008
    Publication date: September 30, 2010
    Applicant: WHITELEY CORPORATION PTY LTD
    Inventors: Reginald Keith Whiteley, Marilyn Emily Karaman, Gregory Stuart Whiteley
  • Publication number: 20100239513
    Abstract: Compositions for effectively delivering a water-soluble active material to a surface comprise: (a) from about 1% to about 30%, by weight of the composition, of a dialkyl quaternary ammonium compound having the formula: ?wherein R1 and R2 are independently C12 to C20 saturated alkyl chains; Y is ?wherein R4 is ethyl or isopropyl; R3 and R5 are independently methyl, ethyl, hydroxyethyl, or hydroxypropyl; m is 1, 2, or 3; n is 1 or 2; p is 0 or 1; and X? is a suitable anion; (b) from about 0.01% to about 10%, by weight of the composition, of water-soluble active material having a ClogP of less than about 2.0; and (c) at least about 60%, by weight of the composition, of water; wherein the compositions contain vesicles having a vesicle permeability index of less than about 1.3.
    Type: Application
    Filed: June 4, 2010
    Publication date: September 23, 2010
    Inventors: Hugo Jean-Marie Demeyere, Gunnel Ingegard Matilda Johnasson, Mangus Bo Nydén
  • Publication number: 20100196504
    Abstract: The present invention relates to specific synergistic active antimicrobial compositions for hygiene disinfectant products like antimicrobial liquid or solid soaps, disinfectant cleansing solutions and disinfectant emulsions for the treatment of skin surface, specifically for the treatment of hand surface and/or for the treatment of technical surfaces like e.g. surgery equipment comprising a mixture comprising or consisting of a) an antimicrobial active amount of 1,2-decanediol of formula 1: and b) an antimicrobial active amount of one or more compounds selected from the group consisting of ethanol, propan-1-ol, propan-2-ol; chlorhexidine digluconate, chloroxylenol, triclosan, triclocarban, benzethonium chloride, methylbenzethonium chloride and benzalkonium chloride.
    Type: Application
    Filed: May 4, 2007
    Publication date: August 5, 2010
    Applicant: SYMRISE GmbH & Co. KG
    Inventors: Gerhard Schmaus, Ravikumar Pillai
  • Publication number: 20100189817
    Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.
    Type: Application
    Filed: April 2, 2008
    Publication date: July 29, 2010
    Inventors: Ronald R. Krueger, William J. Dupps, Steven Trokel, Ivey Thornton
  • Publication number: 20100143428
    Abstract: A stable glutaraldehyde polymer complex solution which includes: (a) glutaraldehyde (OCH(CH2)3CHO) in a 0.005% to 45% m/v concentration; (b) a non-ionic surfactant; (c) a buffer; (d) a sufficient amount of a pH modifier to bring the pH of the solution to within a 6.0 to 9.0 range; and (e) a polymer.
    Type: Application
    Filed: December 14, 2007
    Publication date: June 10, 2010
    Inventors: Antonietta Pamela Martin, William Wyndham-Quin
  • Publication number: 20100137451
    Abstract: The present invention is generally directed to compositions and methods for the treatment of an infectious disease of the foot of an animal. One aspect of the invention is directed to a method for preventing and/or treating one or more infectious diseases of the hoof in animals, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent, wherein the cross-linking agent is not formaldehyde; and administering the composition to a lower leg and hoof area of said animal to prevent and/or treat said one or more infectious diseases. Another aspect of the invention is directed to a copper-free and zinc-free composition for the treatment and/or prevention of one or more infectious diseases of the hoof in animals, comprising at least one cross-linking agent, wherein said cross-linking agent is not formaldehyde.
    Type: Application
    Filed: November 25, 2009
    Publication date: June 3, 2010
    Applicant: AGROCHEM, INC.
    Inventors: John P. DeMarco, Robert J. DeMarco
  • Publication number: 20100119605
    Abstract: Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 13, 2010
    Inventors: Jason C. Isenburg, Matthew F. Ogle
  • Patent number: 7709535
    Abstract: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: May 4, 2010
    Assignees: The University of North Carolina at Chapel Hill, The University of Rochester Medical Center, Androscience Corporation
    Inventors: Kuo-Hsiung Lee, Li Lin, Charles C-Y Shih, Ching-Yuan Su, Junko Ishida, Hironori Ohtsu, Hui-Kang Wang, Hideji Itokawa, Chawnshang Chang
  • Publication number: 20100078393
    Abstract: Provided is a biocidal composition comprising glutaraldehyde and an oxazolidine biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems such as found in oil and natural gas production.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 1, 2010
    Inventor: Bei Yin
  • Publication number: 20090304812
    Abstract: The present invention relates to compositions and applicator devices for providing accurate and localized administration of pharmaceutical compositions containing therapeutic agents to the skin. In particular, the invention relates to compositions which are solid at a temperature of about 250 C or less, and which soften upon continuous contact with the skin of a patient. The present invention allows a user to administer precise doses of a therapeutic agent by highly localized application of the composition to a desired skin region, without contacting surrounding skin regions, or the user's hand.
    Type: Application
    Filed: December 7, 2006
    Publication date: December 10, 2009
    Inventors: John Staniforth, Paul Goggin
  • Patent number: 7595346
    Abstract: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: September 29, 2009
    Assignees: The University of North Carolina at Chapel Hill, The University of Rochester Medical Center, Androscience Corporation
    Inventors: Kuo-Hsiung Lee, Li Lin, Charles C-Y Shih, Ching-Yuan Su, Junko Ishida, Hironori Ohtsu, Hui-Kang Wang, Hideji Itokawa, Chawnshang Chang
  • Publication number: 20090227684
    Abstract: This invention relates to a stabilised aqueous glutaraldehyde solution including 0.005% to 45% m/v, suitably 10% to 45% m/v solution of glutaraldehyde, an alcohol ethoxylate non-ionic surfactant, a buffer and a sufficient amount of a pH modifier to bring the pH of the solution to 6.0 to 8.5. The glutaraldehyde and the alcohol ethoxylate non-ionic surfactant are chemically bound together, suitably by complexing. These stable solutions can be stored for a period of at least six months without the glutaraldehyde polymerizing or the pH dropping below 5.0.
    Type: Application
    Filed: March 13, 2009
    Publication date: September 10, 2009
    Inventor: Antonietta Pamela Martin
  • Publication number: 20090214654
    Abstract: Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
    Type: Application
    Filed: February 20, 2009
    Publication date: August 27, 2009
    Inventors: Jason C. Isenburg, Narendra R. Vyavahare, Matthew F. Ogle
  • Publication number: 20090088483
    Abstract: The invention relates to aqueous suspensions or dispersions (slurries) of minerals and/or fillers and/or pigments containing one or more dialdehydes and one or more formaldehyde cleavers, and to the use of mixtures consisting of one or more dialdehydes and of one or more formaldehyde cleavers for stabilizing aqueous suspensions or dispersions of minerals and/or fillers and/or pigments (slurries) with regard to infestation or deterioration by microorganisms.
    Type: Application
    Filed: March 21, 2006
    Publication date: April 2, 2009
    Inventors: Willem Anker, Marc Hombeck, Louise Sander Hansen
  • Patent number: 7390837
    Abstract: Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for killing bacteria, disinfection, or sterilization, are disclosed. In one aspect, a germicidal composition may include a diluent, and a germicidal compound having the formula: wherein Ar is an aryl group that is selected from the group consisting of phenyl, 4-pyrimidinyl, and 2-(2-nitro-3-formyl-phenyl). In a further aspect, the composition may also include a germicidal efficacy enhancer such as isophthalaldehyde or a combination of isophthalaldehyde and terephthalaldehyde.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: June 24, 2008
    Assignee: Ethicon, Inc.
    Inventors: Peter C. Zhu, Charles G. Roberts
  • Patent number: 7368132
    Abstract: This invention provides compositions and methods for fixing a biological sample, particularly fecal samples for diagnosis of parasitic infection. The fixative composition of the present invention comprises glyoxal (pyruvate aldehyde) and zinc sulfate and permits staining of biological samples without use of toxic compounds, such as formaldehyde and mercury-containing compounds. The fixative is compatible with many diagnostic assays, including trichrome stains, hematoxlin, ELISA, fluorescent assays, and lateral flow assays.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: May 6, 2008
    Assignee: Medical Chemical Corporation
    Inventor: Andrew J. Rocha
  • Patent number: 7291649
    Abstract: Methods of forming germicidal aromatic dialdehydes by hydrolyzing acetals are disclosed. Compositions and kits including both germicidal aromatic dialdehydes and acetals that are capable of being converted to germicides are disclosed. In one aspect, an acetal may be converted to germicide gradually in a deployed germicidal solution to accommodate for loss of the germicide or otherwise to modify the germicidal efficacy of the deployed germicidal solution.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: November 6, 2007
    Assignee: Ethicon, Inc.
    Inventors: Peter C. Zhu, Bobby N. Brewer, Kaitao Lu
  • Patent number: 7019031
    Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: March 28, 2006
    Assignee: The Arizona Disease Control Research Commission
    Inventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
  • Patent number: 6949682
    Abstract: The present invention relates to cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, the method for preparation and the pharmaceutical composition thereof. The cinnamaldehyde derivatives of the present invention can be effectively used as a cell cycle regulator or a cancer cell growth inhibitor, since it has an ability to regulate cell cycle by holding the cells in G2/M stage of the cell division and has activity to inhibit cancer cell growth.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: September 27, 2005
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Byoung-Mog Kwon, Kwang-Hee Son, Dong Cho Han, Sangku Lee, Jong Han Kim, Sung-Gyu Choi, Mi-Young Lee, Sun Bok Jeon
  • Patent number: 6872716
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: March 29, 2005
    Assignee: Sepracor, Inc.
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Patent number: 6734204
    Abstract: Analogs related to oleamide are employed for potentiating the 5-HT2A and 5-HT1A responses to serotonin (5-HT). With respect to the potentiation of the 5-HT2A receptor response, it is disclosed that, of the naturally occurring fatty acids, the primary amide of oleic acid (oleamide) is the most effective potentiating agent of serotonin and that the potentiating activity of oleamide analogs is highly dependent upon their structural features. In particular, the presence, position, and stereochemistry of the 9-cis double bond is required and even subtle structural variations reduce or eliminate activity. Secondary or tertiary amides may replace the primary amide but follow a well-defined relationship requiring small amide substituents suggesting that the carboxamide serves as a hydrogen bond acceptor but not donor. Alternative modifications at the carboxamide as well as modifications of the methyl terminus or the hydrocarbon region spanning the carboxamide and double bond typically eliminate activity.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: May 11, 2004
    Assignee: The Scripps Research Institute
    Inventor: Dale L. Boger
  • Patent number: 6706290
    Abstract: Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: March 16, 2004
    Inventors: Olvai E. Kajander, Neva Ciftcioglu
  • Patent number: 6703383
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: March 9, 2004
    Assignee: Sepracor, Inc.
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Patent number: 6649567
    Abstract: Algal defacement of coated and non-coated porous masonry and wood construction materials is prevented by pre-treatment of the construction material with an aqueous composition of a copolymer that releases 2-propenal (acrolein) over time.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: November 18, 2003
    Assignee: ISP Investments Inc.
    Inventor: William B. Woods
  • Publication number: 20030212118
    Abstract: arboxyalkcylethers are useful for treating eating disorders such as obesity.
    Type: Application
    Filed: November 5, 2002
    Publication date: November 13, 2003
    Inventors: Bruce Jeffrey Auerbach, Donald Eugene Butler
  • Publication number: 20030149094
    Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Application
    Filed: November 26, 2002
    Publication date: August 7, 2003
    Applicant: Esperion Therapeutics, Inc.
    Inventor: Jean-Louis Henri Dasseux